Trials / Not Yet Recruiting
Not Yet RecruitingNCT06970496
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | B019 | B019： Intravenous infusion, 2.0×10\^6 cell/kg-8.0×10\^6 cell/kg |
Timeline
- Start date
- 2025-12-31
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2025-05-14
- Last updated
- 2025-11-20
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06970496. Inclusion in this directory is not an endorsement.